BioNeutra Global Corp (BGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioNeutra Global Corp (BGA) has a cash flow conversion efficiency ratio of -0.004x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$33.44K ≈ $24.19K USD) by net assets (CA$-8.23 Million ≈ $-5.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BioNeutra Global Corp net asset quality index to measure how much of total assets are equity-financed.
BioNeutra Global Corp - Cash Flow Conversion Efficiency Trend (2013–2023)
This chart illustrates how BioNeutra Global Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BGA cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
BioNeutra Global Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNeutra Global Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PHAXIAM Therapeutics S.A.
PA:PHXM
|
-0.540x |
|
Grupo Vasconia S.A.B
MX:VASCONI
|
0.006x |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
N/A |
|
Edri-El
TA:EDRL
|
0.013x |
|
TrustBIX Inc
V:TBIX
|
0.061x |
|
The Real Good Food Company, Inc.
NYSE:RGFC
|
N/A |
|
Tres Or Resources Ltd
V:TRS
|
-0.004x |
|
ZyVersa Therapeutics Inc.
NASDAQ:ZVSA
|
119.987x |
Annual Cash Flow Conversion Efficiency for BioNeutra Global Corp (2013–2023)
The table below shows the annual cash flow conversion efficiency of BioNeutra Global Corp from 2013 to 2023. For the full company profile with market capitalisation and key ratios, see BioNeutra Global Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | CA$-6.19 Million ≈ $-4.48 Million |
CA$683.42K ≈ $494.37K |
-0.110x | +50.57% |
| 2022-12-31 | CA$-3.76 Million ≈ $-2.72 Million |
CA$838.39K ≈ $606.48K |
-0.223x | +14.85% |
| 2021-12-31 | CA$-1.03 Million ≈ $-747.87K |
CA$271.05K ≈ $196.07K |
-0.262x | -112.82% |
| 2020-12-31 | CA$700.92K ≈ $507.03K |
CA$1.43 Million ≈ $1.04 Million |
2.045x | +1273.33% |
| 2019-12-31 | CA$4.75 Million ≈ $3.44 Million |
CA$707.55K ≈ $511.83K |
0.149x | -7.51% |
| 2018-12-31 | CA$18.06 Million ≈ $13.06 Million |
CA$2.91 Million ≈ $2.10 Million |
0.161x | +0.03% |
| 2017-12-31 | CA$13.96 Million ≈ $10.10 Million |
CA$2.25 Million ≈ $1.62 Million |
0.161x | +150.02% |
| 2016-12-31 | CA$15.78 Million ≈ $11.42 Million |
CA$1.02 Million ≈ $734.83K |
0.064x | +102.99% |
| 2015-12-31 | CA$15.19 Million ≈ $10.99 Million |
CA$481.50K ≈ $348.31K |
0.032x | -76.07% |
| 2014-12-31 | CA$10.64 Million ≈ $7.70 Million |
CA$1.41 Million ≈ $1.02 Million |
0.132x | -74.65% |
| 2013-12-31 | CA$1.93 Million ≈ $1.39 Million |
CA$1.01 Million ≈ $728.01K |
0.523x | -- |
About BioNeutra Global Corp
BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, Europ… Read more